Risk of Malignancy with Vedolizumab Versus Tumor Necrosis Factor-α Antagonists in Patients with Inflammatory Bowel Diseases

被引：0
|
作者：
Siddharth Singh
Herbert C. Heien
Lindsey Sangaralingham
Nilay D. Shah
William J. Sandborn
机构：
[1] University of California San Diego,Division of Gastroenterology, Department of Medicine
[2] University of California San Diego,Division of Biomedical Informatics, Department of Medicine
[3] Mayo Clinic,Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery
[4] Mayo Clinic,Division of Health Care Policy and Research, Department of Health Services Research
来源：
Digestive Diseases and Sciences | 2022年 / 67卷
关键词：
Cancer; Safety; Choice; Colitis; Biologics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2510 / 2516
页数：6
相关论文
共 50 条
  • [1] Risk of Malignancy with Vedolizumab Versus Tumor Necrosis Factor-α Antagonists in Patients with Inflammatory Bowel Diseases
    Singh, Siddharth
    Heien, Herbert C.
    Sangaralingham, Lindsey
    Shah, Nilay D.
    Sandborn, William J.
    DIGESTIVE DISEASES AND SCIENCES, 2022, 67 (06) : 2510 - 2516
  • [2] Comparative Risk of Serious Infections With Tumor Necrosis Factor-α Antagonists vs Vedolizumab in Patients With Inflammatory Bowel Diseases
    Singh, Siddharth
    Heien, Herbert
    Herrin, Jeph
    Dulai, Parambir S.
    Sangaralingham, Lindsey
    Shah, Nilay
    Sandborn, William J.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S444 - S445
  • [3] Risk of Serious Infections With Vedolizumab Versus Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Disease
    Kirchgesner, Julien
    Desai, Rishi J.
    Beaugerie, Laurent
    Schneeweiss, Sebastian
    Kim, Seoyoung C.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2022, 20 (02) : 314 - +
  • [4] Comparative Risk of Serious Infections With Tumor Necrosis Factor α Antagonists vs Vedolizumab in Patients With Inflammatory Bowel Diseases
    Singh, Siddharth
    Heien, Herbert C.
    Herrin, Jeph
    Dulai, Parambir S.
    Sangaralingham, Lindsey
    Shah, Nilay D.
    Sandborn, William J.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2022, 20 (02) : E74 - E88
  • [5] Optimizing Therapeutic Drug Monitoring of Tumor Necrosis Factor-α Antagonists in Patients With Inflammatory Bowel Diseases Reply
    Ben-Horin, Shomron
    Ungar, Bella
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2016, 14 (10) : 1509 - 1510
  • [6] Comparative Outcomes and Safety of Vedolizumab vs Tumor Necrosis Factor Antagonists for Older Adults With Inflammatory Bowel Diseases
    Singh, Siddharth
    Iversen, Aske T.
    Allin, Kristine H.
    Jess, Tine
    JAMA NETWORK OPEN, 2022, 5 (09) : E2234200
  • [7] Risk of Infections With Ustekinumab and Tofacitinib Compared to Tumor Necrosis Factor α Antagonists in Inflammatory Bowel Diseases
    Cheng, David
    Kochar, Bharati D.
    Cai, Tianxi
    Ananthakrishnan, Ashwin N.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2022, 20 (10) : 2366 - +
  • [8] Initiation of Tumor Necrosis Factor-α Antagonists and the Risk of Hospitalization for Infection in Patients With Autoimmune Diseases
    Grijalva, Carlos G.
    Chen, Lang
    Delzell, Elizabeth
    Baddley, John W.
    Beukelman, Timothy
    Winthrop, Kevin L.
    Griffin, Marie R.
    Herrinton, Lisa J.
    Liu, Liyan
    Ouellet-Hellstrom, Rita
    Patkar, Nivedita M.
    Solomon, Daniel H.
    Lewis, James D.
    Xie, Fenglong
    Saag, Kenneth G.
    Curtis, Jeffrey R.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 306 (21): : 2331 - 2339
  • [9] Pustular Skin Reaction to Tumor Necrosis Factor Alpha Antagonists in Patients with Inflammatory Bowel Diseases
    Marzano, Angelo V.
    Tavecchio, Simona
    Berti, Emilio
    Gelmetti, Carlo
    Cugno, Massimo
    INFLAMMATORY BOWEL DISEASES, 2015, 21 (11) : E26 - E27
  • [10] RISK OF NEW OR RECURRENT CANCERS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND PRIOR MALIGNANCY EXPOSED TO VEDOLIZUMAB AND ANTI-TUMOR NECROSIS FACTOR AGENTS
    Vedamurthy, Amar
    Gangasani, Nikitha
    Ananthakrishnan, Ashwin
    GASTROENTEROLOGY, 2020, 158 (06) : S671 - S671
12345